Advances in Hepatology

Review Article

Noninvasive Biomarkers of Liver Fibrosis: An Overview

Table 1

AUROC for the direct markers that have been used in assessment of fibrosis in various liver diseases.


Marker	Liver disease evaluated by the markers				AURCO for advanced fibrosis	AURCO for cirrhosis	References
Marker	CHC	CHB	NAFLD	ALD	AURCO for advanced fibrosis	AURCO for cirrhosis	References

PCICP	NA	—	—	NA	NA	NA	[28–30, 82]
PCIIINP	0.69–0.78	—	NA	0.67–0.867	0.67–0.867	0.734	[31, 36, 37, 58, 154, 159]
Type IV collagen	0.73–0.83	—	0.82	NA	0.583–0.83	NA	[30, 41, 42, 58, 154, 159]
HA*	0.821–0.92	0.98	0.97	0.69–0.93	0.69–0.98	0.85–0.93	[31, 32, 41, 44, 46–48, 115, 154, 159–162]
Laminin	0.542–0.82	—	NA	NA	0.46–0.82	NA	[30, 33, 42, 56, 159]
YXL-40	0.7–0.81		NA	NA	0.7–0.81	0.79	[57–59, 154]
MMP-2	0.59				0.59	0.97	[47, 62]
MMP-3	0.88	—	—	—	0.88	NA	[152]
MMP-9	**	—	—	—	NA	NA	[64, 65]
TIMP-1	0.71–0.773	—	—	—	0.68–0.73	0.91	[31, 62, 63, 154]
TIMP-2	0.73	—	—	—	0.73	NA	[63]
TGF-1	NA	—	—	—	—	—	[70, 71]
TGF-	NA	—	—	—	—	—	[70, 71]
PDGF	NA	—	—	—	—	—	[72, 73]

HA: Hyaluronic acid.
**Negative association, MMP-9 decreases with the progression of fibrosis.
NA: Area under receiver operating characteristic (AUROC) is not available.